Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

INO-3107's rolling BLA progresses after FDA support despite delays. Priority Review may expedite approval by late 2025. Click here to read my analysis.

The stock's fall snapped a three-day winning streak.

Inovio Pharmaceuticals Inc. closed 75.39% below its 52-week high of $7.76, which the company reached on August 23rd.

The market expects Inovio Pharmaceuticals (INO) to deliver a year-over-year increase in earnings ... but a powerful factor that might influence its near-term stock price is how the actual results ...